MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-30-2026
ImmuCell Corporation DPO Ratio 2011-2026 | ICCC
Annual DPO Ratio ImmuCell Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19.5 | 11.2 | 4.03 | 13.8 | 22.9 | 58.1 | 29.9 | 38 | 85.6 | 133 | 18.4 | 52.9 | 18.8 | 35.7 | 23.8 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 133 | 4.03 | 37.7 |
Quarterly DPO Ratio ImmuCell Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 5.41 | 5.11 | 3.91 | - | 10.7 | 28.1 | 12.1 | - | 20 | 25.6 | 20.8 | - | 18.7 | 20.8 | 23.1 | - | 27.5 | 32.7 | 17.1 | - | 24.1 | 25.1 | 19.3 | - | 40.3 | 31.7 | 33.3 | - | 49.5 | 64 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 64 | 3.91 | 24.3 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M |  China |
 |
Esperion Therapeutics
ESPR
|
7.93 K | $ 3.13 | 0.55 % | $ 651 M | USA |
 |
Exelixis
EXEL
|
148 | $ 48.2 | 8.51 % | $ 13.1 B | USA |
 |
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | USA |
 |
Fortress Biotech
FBIO
|
400 | $ 2.53 | 2.85 % | $ 70.6 M | USA |
 |
Galapagos NV
GLPG
|
81.9 | $ 28.81 | 1.48 % | $ 2.69 B |  Belgium |
 |
Ionis Pharmaceuticals
IONS
|
815 | $ 77.0 | 2.33 % | $ 12.3 B | USA |
 |
Kamada Ltd.
KMDA
|
106 | $ 8.29 | 0.91 % | $ 260 M |  Israel |
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
Kymera Therapeutics
KYMR
|
46.6 | $ 85.79 | 3.72 % | $ 7.25 B | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
77.8 | $ 231.58 | -0.31 % | $ 4.24 B | USA |
 |
Liquidia Corporation
LQDA
|
209 | $ 41.64 | 3.75 % | $ 3.58 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
75.2 | $ 22.58 | 1.03 % | $ 3.74 B | USA |
 |
MannKind Corporation
MNKD
|
108 | $ 3.61 | 26.17 % | $ 1.1 B | USA |
 |
Advaxis
ADXS
|
143 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M |  Canada |
 |
AIkido Pharma
AIKI
|
1.92 | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
1.59 K | - | -0.23 % | $ 916 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
133 | $ 24.0 | 2.46 % | $ 3.05 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
2.85 K | - | -11.43 % | $ 502 K | USA |